CS
NVO

Candriam SCA’s Novo Nordisk NVO Stock Holding History

Candriam SCA’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed -$3.8M – 821
2023
Q1 		$3.8M Buy
+10
New +$709 0.03% 425
2022
Q2 		– Sell
-42
Closed -$2K – 810
2022
Q1 		$2K Buy
+42
New +$2.16K ﹤0.01% 792
2021
Q4 		– Sell
-46
Closed -$2K – 848
2021
Q3 		$2K Sell
46
-10
-18% -$483 ﹤0.01% 864
2021
Q2 		$2K Sell
56
-2
-3% -$78 ﹤0.01% 867
2021
Q1 		$2K Buy
58
+2
+4% +$71 ﹤0.01% 786
2020
Q4 		$2K Buy
56
+12
+27% +$415 ﹤0.01% 797
2020
Q3 		$2K Sell
44
-49,162
-100% -$1.64M ﹤0.01% 793
2020
Q2 		$1.61M Buy
49,206
+3,048
+7% +$97.3K 0.02% 525
2020
Q1 		$1.31M Buy
46,158
+94
+0.2% +$2.8K 0.01% 609
2019
Q4 		$1.33M Buy
+46,064
New +$1.28M 0.01% 627
2019
Q3 		– Sell
-84
Closed -$2.14M – 793
2019
Q2 		$2.14M Buy
84
+14
+20% +$346 0.03% 503
2019
Q1 		$1.83M Buy
+70
New +$1.72K 0.02% 521

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA's NVO Position: Q2 2023 in Review

Candriam SCA sold out of Novo Nordisk (NVO) in Q2 2023, closing a stake of 10 shares — an estimated $3.8M sold.

Candriam SCA first reported a position in NVO in Q1 2019 and held it in 12 quarters. The position peaked at $3.8M in Q1 2023. 1,197 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

  • Candriam SCA reported no remaining Novo Nordisk position as of Q2 2023 after selling out during the quarter.
  • Candriam SCA sold 10 Novo Nordisk shares in Q2 2023, an estimated $3.8M.
  • Candriam SCA first reported a position in Novo Nordisk in Q1 2019 and held it in 12 quarters.
  • Candriam SCA's Novo Nordisk position peaked at $3.8M in Q1 2023.
  • 1,197 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.